menu
    • menu
    [{"orgOrder":0,"company":"Osivax","sponsor":"European Innovation Council","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"OVX836","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Osivax","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Osivax \/ European Innovation Council","highestDevelopmentStatusID":"8","companyTruncated":"Osivax \/ European Innovation Council"},{"orgOrder":0,"company":"Osivax","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2022","type":"Collaboration","leadProduct":"OVX836","moa":"Nucleoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Osivax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Osivax \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"8","companyTruncated":"Osivax \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"Osivax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"OVX836","moa":"Nucleoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Osivax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Osivax \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Osivax \/ Not Applicable"},{"orgOrder":0,"company":"Osivax","sponsor":"Bpifrance","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2022","type":"Funding","leadProduct":"OVX836","moa":"Nucleoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Osivax","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"Osivax \/ Bpifrance","highestDevelopmentStatusID":"8","companyTruncated":"Osivax \/ Bpifrance"},{"orgOrder":0,"company":"Osivax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"OVX836","moa":"Nucleoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Osivax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Osivax \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Osivax \/ Not Applicable"},{"orgOrder":0,"company":"Osivax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"OVX836","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Osivax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Osivax \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Osivax \/ Not Applicable"},{"orgOrder":0,"company":"Osivax","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2023","type":"Funding","leadProduct":"OVX836","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Osivax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Osivax \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Osivax \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Osivax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"Influenza Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Osivax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Osivax \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Osivax \/ Not Applicable"},{"orgOrder":0,"company":"Osivax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2024","type":"Not Applicable","leadProduct":"Inactivated quadrivalent influenza vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Osivax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Osivax \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Osivax \/ Not Applicable"},{"orgOrder":0,"company":"Osivax","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2023","type":"Funding","leadProduct":"OVX836","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Osivax","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Osivax \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"4","companyTruncated":"Osivax \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"Osivax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2024","type":"Not Applicable","leadProduct":"OVX033","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Osivax","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Osivax \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Osivax \/ Not Applicable"},{"orgOrder":0,"company":"Osivax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2024","type":"Not Applicable","leadProduct":"OVX033","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Osivax","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Osivax \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Osivax \/ Not Applicable"},{"orgOrder":0,"company":"Osivax","sponsor":"KM Biologics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2024","type":"Licensing Agreement","leadProduct":"OVX836","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Osivax","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Osivax \/ KM Biologics","highestDevelopmentStatusID":"14","companyTruncated":"Osivax \/ KM Biologics"}]

    Find Clinical Drug Pipeline Developments & Deals by Osivax

    Menu

    Osivax

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Osivax

                            France arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Osivax

                            France arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OVX836

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : KM Biologics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Osivax and KM Biologics Partner On Universal Flu Vaccine For Japan

                            Details : KM Biologics holds the exclusive license for the development, manufacturing, and commercialization of Osivax’s broad-spectrum OVX836 'universal' influenza vaccine candidates in Japan.

                            Brand Name : OVX836

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            September 10, 2024

                            Lead Product(s) : OVX836

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : KM Biologics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Osivax

                            France arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Osivax

                            France arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OVX033

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Osivax Completes Enrollment for Phase 1 Sarbecovirus Vaccine Candidate OVX033

                            Details : OVX033 is a first-in-class coronavirus vaccine, targetting nucleocapsid (N), a highly conserved internal antigen, which is much less likely to mutate, providing a broader & universal immune response.

                            Brand Name : OVX033

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            June 25, 2024

                            Lead Product(s) : OVX033

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Osivax

                            France arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Osivax

                            France arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OVX836,Inactivated quadrivalent influenza vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Osivax Completes Vaccination of Last Patient in Phase 2a Trial for OVX836 with QIVs

                            Details : OVX836 is Osivax’ broad-spectrum influenza A vaccine candidate, in combination with quadrivalent influenza vaccines is being evaluated for the treatment of Influenza.

                            Brand Name : OVX836

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            March 26, 2024

                            Lead Product(s) : OVX836,Inactivated quadrivalent influenza vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Osivax

                            France arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Osivax

                            France arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OVX033

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Osivax Vaccinates First Participant in Sarbecovirus Vaccine Trial

                            Details : OVX033 is a first-in-class coronavirus vaccine candidate targeting the nucleocapsid, providing a broader immune response due to lower mutation likelihood compared to surface antigens.

                            Brand Name : OVX033

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            February 15, 2024

                            Lead Product(s) : OVX033

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Osivax

                            France arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Osivax

                            France arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OVX836

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : National Institute of Allergy and Infectious Diseases

                            Deal Size : $1.5 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Osivax Receives Over USD 1.5M Grant from NIAID to Advance Development of Broad-Spectrum Influenza Vaccine Cand...

                            Details : The funding will support preclinical studies evaluating the breadth of protection and immune response induced by the company’s lead, broad-spectrum influenza vaccine candidate, OVX836 against pandemic influenza strains.

                            Brand Name : OVX836

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            December 05, 2023

                            Lead Product(s) : OVX836

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : National Institute of Allergy and Infectious Diseases

                            Deal Size : $1.5 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Osivax

                            France arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Osivax

                            France arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OVX836,Influenza Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Osivax Announces Vaccination of First Participant in Phase 2a Clinical Trial Evaluating OVX836 Combined with Q...

                            Details : OVX836, a first-in-class broad-spectrum influenza vaccine candidate that targets the nucleoprotein (NP), a highly conserved internal antigen, is being evaluated in combination with Quadrivalent Influenza Vaccines (QIVs).

                            Brand Name : OVX836

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            June 15, 2023

                            Lead Product(s) : OVX836,Influenza Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Osivax

                            France arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Osivax

                            France arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OVX836

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Bill & Melinda Gates Foundation

                            Deal Size : $1.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Osivax Awarded Grant from a Leading Non-Governmental Organization for OVX836, its Broad-Spectrum Influenza Vac...

                            Details : The funding will support additional research and development of its lead, broad-spectrum influenza vaccine candidate, OVX836 that targets the nucleoprotein (NP), a highly conserved internal antigen.

                            Brand Name : OVX836

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            March 28, 2023

                            Lead Product(s) : OVX836

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Bill & Melinda Gates Foundation

                            Deal Size : $1.0 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Osivax

                            France arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Osivax

                            France arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OVX836

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Osivax Announces Last Patient Last Visit in Two Phase 2a Clinical Trials with Broad-Spectrum Influenza Vaccine...

                            Details : OVX836 targets the nucleoprotein (NP), a highly conserved internal antigen. Unlike surface antigens, NP is much less likely to mutate, providing a broader and more universal immune response.

                            Brand Name : OVX836

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            December 21, 2022

                            Lead Product(s) : OVX836

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Osivax

                            France arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Osivax

                            France arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OVX836,Quadrivalent Seasonal Influenza Subunit Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Osivax Announces Clinical and Preclinical Vaccine Data Presentations at Upcoming Global Influenza Conferences

                            Details : OVX836, targets the nucleoprotein (NP), a highly conserved internal antigen. Unlike surface antigens, NP is much less likely to mutate, providing a broader and more universal immune response.

                            Brand Name : OVX836

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            September 01, 2022

                            Lead Product(s) : OVX836,Quadrivalent Seasonal Influenza Subunit Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Osivax

                            France arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Osivax

                            France arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OVX836,Quadrivalent Seasonal Influenza Subunit Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Bpifrance

                            Deal Size : $10.4 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Osivax Secures EUR 10M Grant from Bpifrance to Support Clinical Development of OVX836, a Broad-Spectrum Influe...

                            Details : Osivax will apply the funds to prepare OVX836 for a Phase 2b field efficacy clinical trial to assess its efficacy against a broad range of circulating strains. OVX836 targets the nucleoprotein (NP), a highly conserved internal antigen.

                            Brand Name : OVX836

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            June 23, 2022

                            Lead Product(s) : OVX836,Quadrivalent Seasonal Influenza Subunit Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Bpifrance

                            Deal Size : $10.4 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth